Latest news with #Amgen
Yahoo
a day ago
- Business
- Yahoo
2 Dow Jones Stocks with Promising Prospects and 1 to Avoid
The Dow Jones (^DJI) is made up of 30 of the most established and influential companies in the market. But even blue-chip stocks can struggle - some are dealing with slowing growth, outdated business models, or increasing competition. Finding the best companies in the Dow Jones isn't always straightforward, and that's why we started StockStory. That said, here are two Dow Jones stocks positioned for long-term growth and one best left off your watchlist. Market Cap: $80.01 billion Producers of the first asthma inhaler, 3M Company (NYSE:MMM) is a global conglomerate known for products in industries like healthcare, safety, electronics, and consumer goods. Why Do We Avoid MMM? Core business is underperforming as its organic revenue has disappointed over the past two years, suggesting it might need acquisitions to stimulate growth Earnings per share have contracted by 3.4% annually over the last five years, a headwind for returns as stock prices often echo long-term EPS performance Eroding returns on capital from an already low base indicate that management's recent investments are destroying value 3M's stock price of $150.49 implies a valuation ratio of 19x forward P/E. Check out our free in-depth research report to learn more about why MMM doesn't pass our bar. Market Cap: $149.7 billion Founded in 1980 during the early days of the biotechnology revolution, Amgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, and manufactures innovative medicines to treat serious illnesses like cancer, osteoporosis, and autoimmune diseases. Why Does AMGN Stand Out? Solid 14.1% annual revenue growth over the last two years indicates its offering's solve complex business issues Revenue base of $34.13 billion gives it economies of scale and some negotiating power Impressive free cash flow profitability enables the company to fund new investments or reward investors with share buybacks/dividends Amgen is trading at $279.50 per share, or 13.3x forward P/E. Is now the right time to buy? See for yourself in our in-depth research report, it's free. Market Cap: $270.4 billion With over 100 million people served across its various businesses and a workforce of more than 400,000, UnitedHealth Group (NYSE:UNH) operates a health insurance business and Optum, a healthcare services division that provides everything from pharmacy benefits to primary care. Why Will UNH Outperform? Massive revenue base of $410.1 billion gives it meaningful leverage when negotiating reimbursement rates Share repurchases over the last five years enabled its annual earnings per share growth of 13.1% to outpace its revenue gains Market-beating returns on capital illustrate that management has a knack for investing in profitable ventures At $298.95 per share, UnitedHealth trades at 9.7x forward P/E. Is now a good time to buy? Find out in our full research report, it's free. Donald Trump's victory in the 2024 U.S. Presidential Election sent major indices to all-time highs, but stocks have retraced as investors debate the health of the economy and the potential impact of tariffs. While this leaves much uncertainty around 2025, a few companies are poised for long-term gains regardless of the political or macroeconomic climate, like our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025). Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today for free. Sign in to access your portfolio
Reuters
3 days ago
- Business
- Reuters
Health Rounds: Amgen blood platelet booster helps patients who need chemotherapy
May 30 (Reuters) - Amgen's (AMGN.O), opens new tab Nplate, which treats low blood platelet counts caused by an autoimmune condition, was highly effective at preventing a similar common and serious complication of powerful chemotherapy cancer drugs, researchers reported, opens new tab ahead of the American Society of Clinical Oncology meeting in Chicago. The 165 patients in the pivotal trial had either colorectal, gastroesophageal, or pancreatic cancer. They were all receiving toxic cancer drugs that caused them to have chemotherapy-induced thrombocytopenia – an abnormally low blood platelet count - after only a single session. A low platelet level 'puts patients with cancer at a high risk of severe or potentially fatal internal bleeding," said study leader Dr. Hanny Al-Samkari of the Massachusetts General Hospital in Boston. It also "impacts the ability to treat patients with the indicated chemotherapy given as it should be, at full dose and on time,' he added. Trial participants received either a weekly subcutaneous injection of Nplate, known chemically as romiplostim, or a placebo. Nplate acts by stimulating the bone marrow to increase platelet production. Of those in the Nplate group, 84% did not need any reductions of their subsequent chemotherapy doses due to a low platelet count, the researchers found. That was true for only 36% of patients in the placebo group. After taking individual risk factors into account, patients receiving Nplate were more than 10 times more likely than patients in the placebo group to continue their cancer treatments without a dose reduction. 'Reduced chemotherapy intensity has been clearly shown to worsen survival of patients... reducing the likelihood of cure in curable patients and shortening the lives of incurable patients,' Al-Samkari said. There are no FDA-approved drugs to treat chemotherapy-induced platelet loss, he noted. 'These results are therefore potentially practice‑changing for a common serious condition encountered routinely in clinical practice worldwide that prevents delivery of on-time, full-dose anti-cancer therapy,' Al-Samkari said. Artificial intelligence can improve a doctor's accuracy at identifying breast cancer patients who could benefit from treatment with drugs that target the HER2 protein on cancer cells, researchers found in a study, opens new tab that will be presented at the ASCO meeting. These drugs, including AstraZeneca's (AZN.L), opens new tab Enhertu, are beneficial even when patients' levels of the protein are extremely low. However, low or ultra-low levels can be hard to detect, leaving some patients misclassified as HER2-negative. About 50% to 60% of breast cancer patients likely fall into the low-HER2 category, according to the U.S. National Cancer Institute. Willingness to use Enhertu to treat breast cancer has far outpaced the ability to determine with certainty which patients might benefit, experts have said. Funded by AstraZeneca, researchers worked with MindPeak to develop a training program to help pathologists assess HER2 levels in breast cancer. They recruited 105 pathologists from 10 countries to take the course and to analyze tumor samples from 20 patients, both with and without AI assistance. The pathologists' accuracy at determining HER2 clinical categories - null, ultra-low, low, or positive - improved from 66.7% without AI to 88.5% with AI. Misclassification of HER2-ultralow cases as HER2-negative occurred in 29.5% of readings without AI but decreased to 4.0% with AI assistance. 'Our study provides the first multinational evidence that artificial intelligence can help enhance accuracy" in determining HER2 clinical categories, "potentially closing critical diagnostic gaps and enabling more patients to have access to new therapies, said Dr. Marina De Brot of the A.C. Camargo Cancer Center in Sao Paulo, Brazil, who led the study. 'Until recently, most of these patients would have not been offered these options,' she said. A cancer immunotherapy drug from China's BeiGene ( opens new tab used in inoperable esophageal cancer may also change the way some operable esophagus tumors are treated, a mid-stage trial suggests. When patients with newly diagnosed esophageal cancer that has begun to grow beyond its original location have completed their standard pre-operative chemotherapy, a second course of treatment that includes BeiGene's Tevimbra given before surgery can significantly improve their outcomes, researchers reported, opens new tab in advance of ASCO 2025. Researchers recruited 87 such patients whose tumors were no longer seen on imaging exams after chemotherapy with paclitaxel and carboplatin, plus radiation. Ordinarily, the next step in their care would be surgery to remove part or all of the esophagus, at which point pathologists would examine the excised tissue to see if any cancer cells remained. Cancer cells lingering after surgery contribute to the more than 50% recurrence rate in these patients, the researchers said. Half the patients in the study received two additional treatments with chemotherapy and Tevimbra, while the rest went directly to surgery. When pathologists examined the tissues removed during surgery, 40.7% of Tevimbra-treated patients were free of any lingering cancer cells, compared with 18.1% of the control group. After accounting for individual risk factors, patients in the Tevimbra group were nearly three times more likely to have what is known as a pathological complete response. One year later, 95.6% of patients in the Tevimbra group were alive without their disease worsening, known as progression-free survival, compared with 77.3% of patients who did not receive the extra treatment before surgery. That difference was not deemed to be statistically significant, however. 'This pioneering study demonstrates that sequential chemo-immunotherapy... significantly improves pathological complete response rates by more than two-fold and shows promising progression-free survival trends with manageable toxicity," the researchers said. They called for larger late-stage trials to confirm the results that could "redefine the standard-of-care.' (To receive the full newsletter in your inbox for free sign up here)
Globe and Mail
4 days ago
- Business
- Globe and Mail
Is Amgen Stock a Buy?
Amgen (NASDAQ: AMGN) is doing something unusual in 2025. The biotech giant's shares are up 7.2% for the year as I write this while most large-cap healthcare stocks struggle; yet it trades at just 13 times forward earnings estimates compared to 21 for the S&P 500. That disconnect between performance and valuation creates an opportunity. With 14 drugs posting double-digit sales growth in the most recent quarter, a promising obesity drug in late-stage trials, and a 3.5% dividend yield, Amgen offers investors a rare combination of growth, income, and value. Here's why this $150 billion pharmaceutical powerhouse deserves a closer look by investors of all stripes. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Broad-based growth defies biotech blues Amgen delivered stellar first-quarter 2025 results in early May that demonstrated the power of its diversified portfolio, with total revenue climbing 9% year-over-year to $8.1 billion and non-GAAP earnings per share surging 24% to $4.90. The company's performance was driven by remarkable strength across multiple therapeutic areas, with 14 products achieving double-digit sales growth during the three months, relative to the same period a year ago. Leading the charge was asthma blockbuster Tezspire at 65%, followed by cancer drug Blincyto with explosive 52% growth, the osteoporosis treatment Evenity at 29%, and cholesterol-lowering Repatha at 27%. What makes Amgen's growth particularly noteworthy is its ability to maintain robust profitability while investing heavily in future innovation. The company's non-GAAP operating margin expanded 2.5 percentage points to 45.7% in the first quarter of 2025, demonstrating exceptional operating leverage even as research and development expenses climbed 12% to support late-stage clinical programs. This includes pivotal investments in MariTide, Amgen's highly anticipated obesity drug that could transform the company's growth trajectory. Pipeline promises next wave of blockbusters While Amgen's current portfolio delivers steady growth, the company's late-stage pipeline could unleash a new era of expansion. The crown jewel is MariTide (maridebart cafraglutide), a differentiated obesity treatment that activates the GLP-1 receptor while antagonizing GIPR. With Phase 3 trials now enrolling patients and additional studies launching throughout 2025, MariTide represents a multibillion-dollar opportunity in the white-hot obesity market. Beyond MariTide, Amgen's pipeline depth is impressive. Rocatinlimab for atopic dermatitis has delivered stellar Phase 3 results across multiple studies, with the Ignite trial showing 42.3% of patients achieving significant skin clearance versus just 12.5% for placebo. In oncology, tarlatamab (Imdelltra) just demonstrated improved overall survival in small cell lung cancer, potentially establishing a new standard of care in second-line small cell lung cancer. The company's biosimilar strategy also provides a competitive edge. With successful launches of Pavblu (Eylea biosimilar) and Wezlana (Stelara biosimilar), plus upcoming biosimilars for blockbusters Opdivo and Keytruda, Amgen is well positioned to capture market share as several high-earning biologics lose patent protection in the coming years. Financial fortress with shareholder rewards Amgen's financial profile stands out in the biotech space. The company generated $1 billion in free cash flow during Q1 2025, up from $0.5 billion a year earlier, providing ample resources for both business development and shareholder rewards. Management raised the quarterly dividend 6% to $2.38 per share, resulting in an attractive 3.5% yield at the current stock price. The balance sheet remains rock-solid even after the $27.8 billion Horizon Therapeutics acquisition. Amgen reduced debt by $2.8 billion in Q1 and maintains the flexibility to pursue strategic opportunities while returning cash to shareholders. Full-year 2025 guidance calls for revenue of $34.3 billion to $35.7 billion and non-GAAP earnings per share of $20.00 to $21.20, representing mid-single-digit growth at the midpoint. Is Amgen stock a buy? With shares trading at a significant discount to the broader market, Amgen stock presents a compelling opportunity for value-conscious investors. The combination of 14 products delivering double-digit growth, a potentially transformative obesity drug in late-stage development, and a generous 3.5% dividend yield makes this biotech giant a buy for investors seeking both growth and income at a reasonable price. Should you invest $1,000 in Amgen right now? Before you buy stock in Amgen, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Amgen wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,389!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $830,492!* Now, it's worth noting Stock Advisor 's total average return is982% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of May 19, 2025
Yahoo
4 days ago
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio
Yahoo
4 days ago
- Business
- Yahoo
Denosumab Market Report 2025-2029 & 2034: Strategic Collaborations and Digital Health Pave the Way for Innovations, First-Line Treatment Boyoubei Gains Traction
Explore the booming denosumab market, projected to reach $5.59 billion by 2029 with a CAGR of 10.9%. Key growth drivers include osteoporosis prevalence, innovative treatments, and strategic partnerships. Major players like Amgen and Boan Biotech are at the forefront, with North America leading and Asia-Pacific emerging rapidly. Denosumab Market Dublin, May 29, 2025 (GLOBE NEWSWIRE) -- The "Denosumab Market Report 2025" has been added to offering. The denosumab market has experienced robust growth, increasing from $3.27 billion in 2024 to an expected $3.7 billion in 2025, registering a CAGR of 13.1%. This growth has been supported by clinical trials, research advancements, FDA approvals, an increased focus on bone health, and strategic partnerships. As the demand continues, projections indicate the market will reach $5.59 billion by 2029, with a CAGR of 10.9% for the forecast period. This anticipated growth is linked to a rising incidence of bone metastases and advancements in both cancer therapies and osteoporosis awareness. Recent studies, including one from the National Center for Biotechnology Information, highlight the prevalence of osteoporosis, with figures such as a 12.7% prevalence in women diagnosed by physicians in Canada. These statistics underscore the expanding need for effective treatments like denosumab, which targets bone resorption, thereby aiding in reducing fracture risks. Key market players are enhancing their offerings, as seen with Boan Biotech's November 2022 introduction of Boyoubei, a denosumab biosimilar. Securing approval from China's National Medical Products Administration, this biosimilar stands unique as the first to receive global marketing approval. Strategies include penetration into the U.S. and European markets with hopes to impact osteoporosis treatment guidelines. Strategic collaborations are shaping the market. For instance, in June 2022, Organon entered into a partnership with Henlius to commercialize biosimilar candidates referencing Prolia and Xgeva (Denosumab). This alliance emphasizes Organon's commitment to affordable healthcare, particularly focusing on women's health. Major companies in this market include Johnson & Johnson, F. Hoffmann-La Roche Ltd., Novartis International AG, and Amgen Inc., among others. With North America leading the market in 2024, Asia-Pacific is expected to be the fastest-growing region due to rising healthcare advancements and awareness. The denosumab market includes sales of calcium and vitamin D supplements, with values representing factory-gate sales, encompassing the goods sold by manufacturers to various entities. The market also covers comprehensive reports addressing market size, regional shares, and detailed segments, providing a holistic perspective of industry trends. This market, valued in USD unless specified, includes revenues from direct sales, highlighting its importance across multiple geographies, including Asia-Pacific, Western and Eastern Europe, North America, and beyond. Denosumab, as a monoclonal antibody, plays a critical role in treating bone-related conditions, specifically osteoporosis and bone metastases, revealing its ongoing importance in the healthcare landscape. Key Attributes: Report Attribute Details No. of Pages 200 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $3.7 Billion Forecasted Market Value (USD) by 2029 $5.59 Billion Compound Annual Growth Rate 10.9% Regions Covered Global Scope: Markets Covered: By Drug Classification:Prolia, Xgeva, Others By Type:60 mg, 120 mg By End-Users:Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers Companies Featured Johnson & Johnson F. Hoffmann-La Roche Ltd. Novartis International AG Sanofi SA GlaxoSmithKline plc Eli Lilly and Company Amgen Inc. Asahi Kasei Corporation Teva Pharmaceutical Industries Ltd. Astellas Pharma Inc. Daiichi Sankyo Company, Limited Mylan N.V. Sandoz International GmbH Daiichi Sankyo Company Limited Aurobindo Pharma Limited Cipla Limited Dr. Reddy's Laboratories Ltd. Hikma Pharmaceuticals PLC Celltrion Inc. Amneal Pharmaceuticals Inc Cadila Healthcare Limited Lupin Limited Biocon Limited Torrent Pharmaceuticals Ltd. Jubilant Life Sciences Limited Ajanta Pharma Limited For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Denosumab Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
